Gene · 4605
MYBL2: MYB proto-oncogene like 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. MYBL2: MYB proto-oncogene like 2. Genes, record 4605. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4605
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P10244 | Myb-related protein B | 700 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents61
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 69719 | P10244 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 268 | P10244 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4325 | P10244 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 15323 | P10244 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 268 | P10244 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 15323 | P10244 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4325 | P10244 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 15323 | P10244 | Espacenet |
| JP 2024539140 A | 2024-10-28 | 5 | P10244 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 15162 | P10244 | Espacenet |
1 to 10 of 61
See all 61 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,474
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | MYBL2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 18 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 14 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 9 | 2025 |
| P50CA058223 | SPORE in Breast Cancer | 8 | 2025 |
| P30CA014520 | UW Comprehensive Cancer Center Support | 6 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 6 | 2025 |
| ZIAAG000393 | Influence of Post-transcriptional Gene Regulation on Cell Senescence and Aging | 6 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 5 | 2025 |
| P30CA044579 | University of Virginia Cancer Center Support Grant | 5 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 4 | 2025 |
1 to 10 of 1,474Source NIH's project files
See all 1,474 nih grantsPapers2,561
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| An IGF2BP2-MYBL2-HMGB2 Signaling Axis Promotes Macrophage Immune Evasion in Hepatocellular Carcinoma. | Cancer Commun (Lond) | 2026 | 42819712 | PubTator, text mining | PubMed |
| Parental B-MYB/FOXM1 controls mitotic E2F to determine daughter cell fate. | bioRxiv | 2026 | 42817988 | PubTator, text mining | PubMed |
| ZFP335-MYBL2 transcriptional axis orchestrates Th17 cell differentiation and psoriatic inflammation. | J Immunol | 2026 | 42804764 | PubTator, text mining | PubMed |
| TRRAP enables MMB-dependent mitotic transcription and determines sensitivity to CHK1 inhibition. | Cell Rep | 2026 | 42731029 | PubTator, text mining | PubMed |
| MYBL2 promotes malignant phenotypes and M2-like macrophage polarization through CCL2 in non-small cell lung cancer. | Mol Cell Biochem | 2026 | 42720907 | PubTator, text mining | PubMed |
| KDM1A/HDAC2-driven epigenetic dysregulation maintains a drug-resistant, relapse-initiating glioblastoma cell niche at the peri-tumoral margin. | Biochem Pharmacol | 2026 | 42685875 | PubTator, text mining | PubMed |
| B-MYB (MYBL2): from cell cycle regulator to an oncogenic player. | Biochim Biophys Acta Rev Cancer | 2026 | 42674117 | PubTator, text mining | PubMed |
| Integrative single-nucleus transcriptomic analysis identifies UBE2C+ proliferative tumor cells and immune-stromal regulatory crosstalk in small cell lung cancer. | Front Immunol | 2026 | 42614523 | PubTator, text mining | PubMed |
| Hypoxia drives ferroptosis resistance and immunosuppression in hepatocellular carcinoma by inducing UBASH3B-mediated glutamine metabolism reprogramming and CXCL8 expression. | Redox Biol | 2026 | 42594485 | PubTator, text mining | PubMed |
| Proteome-wide Multi-omics Profiling of Osteosarcoma Transcription Factor Networks. | J Mol Biol | 2026 | 42526587 | PubTator, text mining | PubMed |
1 to 10 of 2,561
See all 2,561 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4605
GET https://conductscience.org/api/genes/v1/4605/patents?page=2